Autres langues BioSenic SA

Actions

BIOS

BE0974280126

Temps réel Euronext Bruxelles Autres places de cotation 11:11:20 30/04/2024			Varia. 5j.	Varia. 1 janv.
0,0154 ^EUR	-1,28 %		-21,43 %	-74,84 %

24/04	Biosenic : reporte à juin la publication de ses résultats annuels	AO
11/04	Biosenic : lancement d'un plan de restructuration de la dette	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles	26/04
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04
BioSenic S.A. : Transparency notifications received from François Rieger	18/04
BioSenic provides further information on its restructuring plan	12/04
BioSenic : summary bonds refinancing_20240411	12/04
BioSenic dient herstructureringsplan in	11/04
Biosenic : lancement d'un plan de restructuration de la dette	11/04
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04
BioSenic presenteert succesvolle studiedata op het Systemic Sclerosis World Congress 2024	20/03
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress	20/03
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease	12/03
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	12/03
Lotus Bakeries en Argenx in trek in lichtgroen Brussel	05/02
Brussel licht hoger en Ageas in de problemen	05/02
Lotus primus in Brussel	05/02
Brussel start handelsweek vermoedelijk neutraal	05/02
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide	05/02
BioSenic haalt half miljoen euro op	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioSenic SA

Actions

BIOS

BE0974280126

Autres langues

Filtres